P/E at 35.63 vs Industry's 36.72: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Slight Discount in a High-P/E Sector

The current P/E of Sun Pharmaceutical Industries Ltd stands at 35.63, marginally below the Pharmaceuticals & Biotechnology industry average of 36.72. This subtle discount contrasts with the sector’s generally elevated valuations, reflecting investor willingness to pay a premium for growth and stability in this large-cap stock with a market capitalisation of ₹4,53,330.35 crores. The P/E differential, though modest, suggests that the market may be pricing in some near-term challenges or a cautious outlook relative to peers. Previously rated Buy, what is Sun Pharma’s current rating? This valuation context is crucial for investors weighing the stock’s relative attractiveness within the sector.

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple horizons reveals a mixed performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 16.18% gain, significantly outperforming the Sensex’s decline of 5.52%. This outperformance extends to longer-term horizons as well, with three-year returns at 66.60% versus the Sensex’s 18.76%, and five-year returns at 141.32% compared to 38.66% for the benchmark. However, the short-term momentum tells a different story. The stock has declined by 2.36% over the past week and 2.26% over the last month, underperforming the Sensex’s respective falls of 1.06% and 1.30%. Even the three-month return of 0.39% lags behind the Sensex’s 2.57% gain, signalling a recent loss of relative strength. This divergence raises the question: is this a temporary setback or indicative of a deeper shift in momentum?

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is characterised by a nuanced moving average (MA) configuration. The stock currently trades above its 100-day and 200-day moving averages, suggesting that the longer-term trend remains intact. However, it is positioned below the 5-day, 20-day, and 50-day moving averages, indicating short-term weakness or consolidation. This pattern often reflects a recent pullback within a broader uptrend, but it can also signal the early stages of a more sustained correction. The stock’s four-day consecutive decline, resulting in a 3.73% loss, underscores this short-term pressure. The 5% surge partially reverses a 6.45% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 34 stocks that have declared results, 14 reported positive outcomes, 15 remained flat, and 5 posted negative results. This distribution highlights a sector grappling with varied operational and market challenges. Within this environment, Sun Pharmaceutical Industries Ltd has managed to maintain relative stability, though its recent short-term underperformance suggests it is not immune to sector headwinds. The stock’s inline performance today, with a 0.69% gain compared to the sector’s flat movement, further emphasises its resilience. Should investors in Sun Pharma hold, buy more, or reconsider?

Rating Reassessment: From Buy to Hold

On 17 Aug 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from Buy to Hold by MarketsMOJO. This change reflects a recalibration of the stock’s risk-reward profile amid evolving market conditions and valuation considerations. The Mojo Score currently stands at 67.0, indicating a moderate outlook. The reassessment aligns with the observed valuation premium compression and the recent short-term performance challenges. Investors may find it instructive to analyse how this rating update fits within the broader sector dynamics and the stock’s technical signals — what is the current rating?

Collective Data Insights: Balancing Valuation and Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a valuation slightly below its industry peers, with a strong long-term performance record but recent short-term softness. The moving average configuration suggests the stock is navigating a phase of consolidation or mild correction within a longer-term uptrend. Sector results are mixed, reflecting broader industry challenges that may be influencing investor sentiment. The rating reassessment from Buy to Hold underscores a more cautious stance, balancing the stock’s historical strength against current market realities. Should investors in Sun Pharma hold, buy more, or reconsider?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →